Cancer Medicine 2016; 5(11):3310--3325

Introduction {#cam4915-sec-0001}
============

Gallbladder cancer (GBC) is rare, although the incidence varies greatly in different parts of the world. It is also highly lethal, with a 5‐year survival of approximately 12% [1](#cam4915-bib-0001){ref-type="ref"}, [2](#cam4915-bib-0002){ref-type="ref"}, [3](#cam4915-bib-0003){ref-type="ref"}, [4](#cam4915-bib-0004){ref-type="ref"}. Although gallstones are a major risk factor for GBC in high‐risk areas like Chile, presenting in \>95% of GBC cases [5](#cam4915-bib-0005){ref-type="ref"}, it has been estimated that only 1% of gallstone patients will develop GBC [6](#cam4915-bib-0006){ref-type="ref"}.

Chronic biliary infection with *Salmonella enterica* serovar Typhi (*S. *Typhi), the causative agent of typhoid fever, has been proposed as one possible additional risk factor for GBC [2](#cam4915-bib-0002){ref-type="ref"}. This hypothesis developed from a case report of a woman who had documented typhoid fever for 30 years before hospitalization due to GBC, with *S. *Typhi subsequently isolated from bile and from the wall of the gallbladder [7](#cam4915-bib-0007){ref-type="ref"}. Several retrospective studies in the United States [8](#cam4915-bib-0008){ref-type="ref"}, Denmark [9](#cam4915-bib-0009){ref-type="ref"}, and Scotland [10](#cam4915-bib-0010){ref-type="ref"} have provided strong evidence that chronic *S. *Typhi carriers have a significantly higher risk of death from GBC in comparison with the general population. More recently, several case--control studies have reported significant associations between *S. *Typhi and GBC, many of them coming from Northern India, where both typhoid fever and GBC are endemic. These associations are not always supported by evidence of *S. *Typhi from biologic specimens, but methods for detecting *S. *Typhi in the gallbladder may not be sufficiently sensitive, while Vi antibody serostatus may not reflect *S. *Typhi infection in the gallbladder itself. Thus, the nature of the association between *S. *Typhi and GBC remains unclear and is hindered by the limitations of the assays.

The hypothesis that *S. *Typhi may be linked to GBC is especially relevant in Chile, which has among the highest GBC incidence rates in the world (12.8 per 100,000 in women and 6.3 per 100,000 in men) [11](#cam4915-bib-0011){ref-type="ref"}, [12](#cam4915-bib-0012){ref-type="ref"}, [13](#cam4915-bib-0013){ref-type="ref"}. The annual country‐wide incidence of typhoid fever ranged from \~40 to 60 cases per 100,000 population between 1970 and 1976 and then rose abruptly from 1977 to 1984, with incidence rates ranging from \>90 to 121 cases per 100,000 [2](#cam4915-bib-0002){ref-type="ref"}, [14](#cam4915-bib-0014){ref-type="ref"}. Vaccination of large cohorts of schoolchildren between 1980 and 1985 with live oral typhoid vaccine lowered the annual rates in Santiago by 1990. Several sanitation interventions introduced following the 1991 outbreak of cholera lowered the annual rates dramatically beginning in 1992 to \<20 cases per 100,000 and to \<10 cases per 100,000 by 2000. Although *S. *Typhi exposure is now at low levels, exposure to *S*. Typhi when it was endemic decades ago could affect current trends in GBC rates if chronic carriage increases the risk of GBC. Given that GBC is the second leading cause of cancer death in Chilean women [11](#cam4915-bib-0011){ref-type="ref"}, [15](#cam4915-bib-0015){ref-type="ref"}, understanding the role of *S. *Typhi in gallbladder carcinogenesis is particularly relevant for early detection and prevention strategies.

We hypothesized that GBC cancer cases would have higher titers of IgG antibody to the Vi capsular polysaccharide of *S. *Typhi than controls with or without gallstones. We tested this hypothesis in 39 GBC cases, 40 gallstone controls, and 39 population‐based controls without gallstones, recruited from three public hospitals and the areas that they service in Chile. We also used culture and quantitative polymerase chain reaction (qPCR) in an attempt to detect *S*. Typhi in a subset of participants with bile, gallstone, gallbladder tissue, or stool samples available. In addition, we conducted a meta‐analysis to evaluate the effects of study design issues, such as differences in referent groups, assays, and geographical region.

Materials and Methods {#cam4915-sec-0002}
=====================

Study population {#cam4915-sec-0003}
----------------

As recently described [16](#cam4915-bib-0016){ref-type="ref"}, we enrolled incident GBC cases without prior cancer between April 2012 and August 2013 through rapid ascertainment in three public hospitals in Chile. We recruited age‐ and sex‐matched gallstone controls who had cholecystectomy in the same week as the case and age‐ and sex‐matched population‐based controls identified from the registry of beneficiaries at the local health center or through neighborhood sampling. Eighty‐four percent of GBC cases (49/58), 88% of gallstone controls (37/42), and 60% of population‐based controls consented to participate (49/82). We included all participants with serum available. Eight population‐based controls had ultrasound‐detected gallstones. These individuals were recoded as gallstone controls. We also excluded excluded two population‐based controls with unknown gallstone status. Therefore, the current analysis included 39 GBC cases, 40 gallstone controls. Based on a previous meta‐analysis that provided a summary OR of 3.5 for antibody‐based *S. *Typhi detection and GBC [17](#cam4915-bib-0017){ref-type="ref"}, we estimated that with 39 GBC cases and two controls per case (gallstone and population‐based controls combined), we would have more than 80% power to confirm this association in our study population. The study was approved by institutional review boards of the US National Cancer Institute, Pontificia Universidad Católica, the Chilean Ministry of Health, and each hospital that contributed to the study as required. All participants provided written consent. Biospecimens were stored at −80°C.

Laboratory testing {#cam4915-sec-0004}
------------------

### Elevated titers of serum antibody against Vi capsular polysaccharide {#cam4915-sec-0005}

Serum samples were blindly tested for IgG antibodies to *S. *Typhi Vi capsular polysaccharide in the Applied Immunology Section of the Center for Vaccine Development, University of Maryland School of Medicine. Anti‐Vi antibody titers were measured by ELISA with modifications of the methods of Losonsky et al. [18](#cam4915-bib-0018){ref-type="ref"} and Wahid et al. [19](#cam4915-bib-0019){ref-type="ref"}. We used biotinylated Vi (kindly provided by Dr. Andrew Lees). In addition, we ran a human Vi antibody standard [20](#cam4915-bib-0020){ref-type="ref"} that allowed us to convert ELISA unit titers to *μ*g/mL of IgG Vi antibody. The lower limit of detection was 0.04 *μ*g/mL. Based on the distribution of Vi antibody titers among cases and controls (Fig. [1](#cam4915-fig-0001){ref-type="fig"}), we used ≥0.3 *μ*g/mL as the cut off for high Vi antibody titer levels. We also conducted sensitivity analyses using cut offs of 0.2 (the upper limit for seropositivity considering an assay variation of up to 25%), 0.5, 1, and 1.5 *μ*g/mL. We included duplicate aliquots for four individuals. The within subject coefficient of variation for these subjects was 5%.

![Distribution of detectable Vi antibody levels among gallbladder cancer cases, gallstone controls, and population‐based controls.](CAM4-5-3310-g001){#cam4915-fig-0001}

### Microbial assays {#cam4915-sec-0006}

We tested for evidence of bacteria in tissue (*N* = 35), gallstones (*N* = 35), bile (*N* = 10), and stools (*N* = 35) from the subset of participants who had sufficient material available. Microbial assays were performed in the Laboratory of Microbiology at Pontificia Universidad Católica de Chile as described below.

Culture and DNA extraction {#cam4915-sec-0007}
--------------------------

### Stool {#cam4915-sec-0008}

Thirty‐five samples from 13 GBC cases, nine gallstone controls, and 13 population‐based controls were enriched in selenite and ox bile broth (Oxoid) and plated in Hektoen agar. The bacterial species among the suspicious colonies were identified by matrix‐assisted laser desorption/ionization time‐of‐flight mass spectrometry (MALDI‐TOF). Selenite broth cultures were centrifuged and DNA was extracted with the QIAamp DNA Stool Mini kit.

### Gallbladder tissue, bile, and gallstones {#cam4915-sec-0009}

A subset of participants had gallbladder tissue (10 GBC cases, 25 gallstone controls), bile (three GBC cases, seven gallstone controls), and gallstones (eight GBC cases, 28 gallstone controls) collected aseptically. Gallbladder tissue, bile, or gallstones were enriched in selenite and Tryptic soy broth. If the tissue sample was large, it was cut into smaller pieces prior to culture. One gallstone was cultured per participant. One mL of bile was cultured per participant. After overnight incubation, one aliquot of broth was used for culture, and one was used for DNA extraction. Cultures exhibiting visible growth were plated on blood and chocolate agar, and colonies that grew were identified by MALDI‐TOF. DNA was extracted using the QIAamp DNA Mini Kit according to the manufacturer\'s instructions. For DNA extraction from tissue, cultured tissue samples were homogenized, and 25 mg of tissue was combined with 1 mL of the culture broth and centrifuged at 1200 g for 2 min. DNA was extracted from the pellet. Supernatant was discarded and 180 *μ*L of lysis buffer and 20 *μ*L of proteinase K were added to the pellet. After two washing steps, DNA was eluted in 50 *μ*L of elution buffer. For DNA extraction from gallstones, cultured gallstones were sonicated in the culture medium for 1 min at 50 kHz, and 1 mL of culture broth was centrifuged for 2 min at 1200 g. DNA extraction continued as described above. For DNA extraction from bile, 1 mL of cultured bile was centrifuged for 2 min at 1200 g. DNA extraction continued as described above.

### Detection of specific pathogens by PCR {#cam4915-sec-0010}

All samples (bile, tissue, stones, stool) were analyzed by real‐time PCR (qPCR) to detect *S*. Typhi, employing primers to amplify *fliC,* which encodes the *S*. Typhi Phase 1 flagellin subunit (Hd) [21](#cam4915-bib-0021){ref-type="ref"}. The analytical sensitivity of the PCR was 14.5 *S*. Typhi genomes per qPCR reaction (data not shown). Conversely, DNA extracted from clinical isolates of *S*. Typhimurium, *S*. Choleraesuis, *S*. Paratyphi A, or *S*. Enteritidis did not amplify. Gel‐based PCR was used to detect *Salmonella* species, utilizing primers that amplify *invA* encoding a *Salmonella* Pathogenicity Island 1 protein required for invasion of epithelial cells [22](#cam4915-bib-0022){ref-type="ref"}). PCR products for *Salmonella* species were visualized on agarose gels, 1.5%. DNA extracted from a clinical isolate of *S*. Typhi was used as the positive control in qPCR and gel‐based PCR tests. PCR‐grade water was used as the negative control in all tests. Human RNAse P gene was used as the internal quality control to ensure proper DNA extraction and the absence of PCR inhibitors [23](#cam4915-bib-0023){ref-type="ref"}, [24](#cam4915-bib-0024){ref-type="ref"}.

Statistical analysis {#cam4915-sec-0011}
--------------------

We compared participants using the Kruskal--Wallis test for difference in median or nonzero correlation chi‐square test for categorical comparisons (Table [1](#cam4915-tbl-0001){ref-type="table-wrap"}). Conditional and unconditional logistic regression models produced similar results for the association of *S. *Typhi with GBC compared to gallstone controls and population‐based controls; thus, we used unconditional logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (95% CIs). We evaluated the association between high titers of anti‐Vi antibody seropositivity (≥0.3 *μ*g/mL for the primary analysis) and GBC compared gallstone controls and population‐based controls combined using standard logistic regression. In addition, we compared GBC to gallstone controls and population‐based controls separately using polytomous logistic regression. We also explored if high Vi antibody titer levels were associated with gallstones by comparing gallstone controls to population‐based controls without gallstones. Using forward modeling, we assessed potential confounders including continuous age, gender, study site (Concepcion and Temuco, which have high risk of GBC, vs. Santiago), self‐reported Mapuche ancestry, BMI (based on self‐report of weight more than 3 years ago or average adult weight and categorized according to the WHO guidelines: BMI \<18.50 = underweight, 18.50--24.99 = normal weight, 25.00--29.99 = overweight, ≥30 = obese), education (ordinal categories of less than 6 years of education, 7--9 years, 10--12 years, and 13 years of more), diabetes, smoking (ever vs. never), family history of GBC. Gender and education changed the ORs by more than 10% and were therefore retained in the adjusted models. All analyses were conducted using SAS 9.3 (SAS Institute Inc., Cary, NC).

###### 

Characteristics of gallbladder cancer cases (GBC), gallstone patients, and population‐based controls tested for *Salmonella* Typhi Vi antibody seropositivity

                                                                                                                           GBC(*N* = 39)   Gallstone controls(*N* = 40)   Population‐based controls(*N* = 39)   *P*‐value[b](#cam4915-note-0004){ref-type="fn"}
  ------------------------------------------------------------------------------------------------------------------------ --------------- ------------------------------ ------------------------------------- -------------------------------------------------
  Age, median (range)                                                                                                      62 (41--77)     60 (40--79)                    66 (37--75)                           0.9
  Male gender, *N*(%)[a](#cam4915-note-0003){ref-type="fn"}                                                                7 (17.9)        7 (18.4)                       8 (20.5)                              0.8
  High‐risk site (Concepcion or Temuco), N(%)                                                                              20 (51.3)       18 (45.0)                      15 (38.5)                             0.3
  Self‐reported Mapuche ancestry, *N*(%)[a](#cam4915-note-0003){ref-type="fn"}                                             4 (10.3)        2 (5.4)                        2 (5.1)                               0.4
  Education level, *N*(%)[a](#cam4915-note-0003){ref-type="fn"}                                                                                                                                                 
  ≤6 years                                                                                                                 21 (53.8)       17 (44.7)                      12 (30.8)                             0.004
  7--9 years                                                                                                               9 (23.1)        8 (21.1)                       5 (12.8)                              
  10--12 years                                                                                                             6 (15.4)        9 (23.7)                       13 (33.3)                             
  ≥13 years                                                                                                                3 (7.7)         4 (10.5)                       9 (23.1)                              
  Body mass index weight category, N(%)[a](#cam4915-note-0003){ref-type="fn"} ^,^ [c](#cam4915-note-0005){ref-type="fn"}                                                                                        0.7
  Normal weight                                                                                                            14 (41.2)       8 (25.0)                       12 (33.3)                             
  Overweight                                                                                                               12 (35.3)       15 (46.9)                      16 (44.4)                             
  Obese                                                                                                                    8 (23.5)        9 (28.1)                       8 (22.2)                              
  Diabetes, N(%)[a](#cam4915-note-0003){ref-type="fn"}                                                                     10 (25.6)       6 (16.2)                       6 (15.4)                              0.3
  Smokers, N(%)[a](#cam4915-note-0003){ref-type="fn"}                                                                      12 (30.8)       14 (37.8)                      21 (53.8)                             0.04
  Family history of GBC, N(%)[a](#cam4915-note-0003){ref-type="fn"}                                                        2 (7.1)         0 (0.0)                        1 (3.6)                               0.5
  Self‐reported typhoid fever, N(%)[a](#cam4915-note-0003){ref-type="fn"}                                                  3 (8.1)         2 (5.7)                        3 (7.7)                               0.9
  Elevated Vi antibody seropositivity, N(%)[d](#cam4915-note-0006){ref-type="fn"}                                          6 (15.4)        2 (5)                          1 (2.6)                               0.03

Percentages exclude individuals with missing data.

Kruskal--Wallis test for difference in median or nonzero correlation chi‐squared test for categorical comparisons.

Based on self‐report of weight more than 3 years ago or average adult weight.

A titer ≥0.3ug/mL was considered as having elevated Vi antibody titers.

John Wiley & Sons, Ltd

Literature review and meta‐analysis {#cam4915-sec-0012}
-----------------------------------

We searched for published studies on *Salmonella* and GBC in MEDLINE (via PubMed) through 10 February 2016 using the terms ("hepatobiliary cancer" OR "hepatopancreatobiliary cancer" OR "biliary tract cancer" OR "biliary tract carcinoma" OR "bile duct cancer" OR "bile duct carcinoma" OR "gallbladder cancer" OR "gall bladder cancer" OR "gallbladder carcinoma" OR "gall bladder carcinoma") AND ("Salmonella Typhi" OR Salmonella OR "typhoid fever" OR "S. typhi" OR "S typhi" OR "S. Typhi" OR "S Typhi" OR "S. paratyphi" OR "S paratyphi" OR "S. Paratyphi" OR "S Paratyphi"). No restrictions were placed on language or publication starting date. Peer‐reviewed publications that evaluated *Salmonella* and GBC were eligible if they either reported or had calculable relative risks (risk ratios, rate ratios, ORs, or standardized incidence or mortality rates, hereafter termed ''relative risks'' and referred to RRs) and corresponding 95% confidence intervals (CIs) for the association between *Salmonella* and GBC.

We abstracted RRs and 95% CIs if they were reported, or calculated them ourselves for the association between *Salmonella* and GBC. For author‐calculated RRs, 0.5 was added to each of the four interior cells if one of the cells contained zero. Abstracted data included *Salmonella* detection method (culture, antibodies against somatic antigens (TO) or flagellar antigens (TH), antibodies against VI antigen, nested PCR for the *S*. Typhi flagellin subunit gene, self‐report, physician‐diagnosed, *S*. Typhi lypopolysaccharide), biospecimen if applicable (stool, bile, serum, gallstones, tissue), outcome (prevalent GBC, incident GBC, GBC mortality, hepatobiliary cancer mortality, hepatobiliary cancer incidence), and other study characteristics (e.g., sample size, study design, geographic location). For publications based on the same study population [10](#cam4915-bib-0010){ref-type="ref"}, [25](#cam4915-bib-0025){ref-type="ref"}, [26](#cam4915-bib-0026){ref-type="ref"}, [27](#cam4915-bib-0027){ref-type="ref"}, [28](#cam4915-bib-0028){ref-type="ref"}, [29](#cam4915-bib-0029){ref-type="ref"}, [30](#cam4915-bib-0030){ref-type="ref"}, [31](#cam4915-bib-0031){ref-type="ref"}, [32](#cam4915-bib-0032){ref-type="ref"}, [33](#cam4915-bib-0033){ref-type="ref"}, [34](#cam4915-bib-0034){ref-type="ref"}, [35](#cam4915-bib-0035){ref-type="ref"}, we used the article with the largest number of participants unless multiple articles could contribute to separate analyses. We initially extracted data on two studies that we later excluded from analyses because they had ecological [36](#cam4915-bib-0036){ref-type="ref"} or case series [34](#cam4915-bib-0034){ref-type="ref"} study designs.

We evaluated the association between *Salmonella* and GBC using stratified random‐effects meta‐analysis and examined key study characteristics and variation across studies using restricted maximum likelihood metaregression. Some studies provided multiple RRs with differing *Salmonella* detection methods or outcome referent groups. In these cases, we applied the following decision rules to select one RR per study for any given analysis: (1) if crude and adjusted estimates available, chose adjusted estimate; (2) choose results with the largest number of cases, then the largest number of controls; if the number of cases is similar and the number of controls very different, base choice on the largest number of controls; (3) if there are multiple results with the same number of cases and controls but different *S. *Typhi assays, choose the more specific assay (culture, DNA, Vi antibody seropositivity, then Widal). We used Cochran\'s Q two‐sided homogeneity *P*‐value [37](#cam4915-bib-0037){ref-type="ref"} to evaluate heterogeneity in RRs and funnel plots to assess asymmetry, which can reflect publication bias, random error, or study characteristics associated with sample size [38](#cam4915-bib-0038){ref-type="ref"}, using Begg rank correlation [39](#cam4915-bib-0039){ref-type="ref"} and Egger regression [40](#cam4915-bib-0040){ref-type="ref"}.

Results {#cam4915-sec-0013}
=======

The current analysis included 39 GBC cases, 40 gallstone controls, and 39 population‐based controls with serum available. The sociodemographic characteristics were generally similar across cases and controls, although GBC cases were less likely to have higher education (*χ* ^2^ *P* = 0.004) or to be smokers (*χ* ^2^ *P* = 0.04) (Table [1](#cam4915-tbl-0001){ref-type="table-wrap"}). In addition, 15.4% of GBC cases had high Vi antibody levels (≥0.3 *μ*g/mL) compared to 5.0% of gallstone controls and 2.6% of population‐based controls.

High Vi antibody titer levels were associated with an increased risk of GBC compared to all controls combined using standard logistic regression \[OR (95% CI): 4.6 (1.1--19.5)\], and the association remained elevated after adjustment for gender and education \[4.0 (0.9--18.3)\]. GBC cases were more likely to have high Vi antibody titer levels than combined controls even when higher or lower cut offs were used to define high Vi antibody titer level (Table S1). Comparing to gallstone and population‐based controls separately using polytomous logistic regression, the gender‐ and education‐adjusted ORs for elevated Vi antibody seropositivity and GBC were 3.1 (0.6--17.7) versus gallstone controls, and 5.6 (0.6--52.8) versus population‐based controls. Gallstone controls were about two times as likely to be Vi antibody seropositive compared to population‐based controls \[1.8 (0.1--21.9)\], although the estimates were imprecise.

None of the stool specimens analyzed had Salmonella Typhi or non‐Typhi *Salmonella*. One GBC case and one gallstone control were positive for non‐Typhi *Salmonella* in tissue and bile specimens, respectively, but none had evidence of *S*. Typhi (Table S2).

The meta‐analysis included data from 22 published studies on *Salmonella* and GBC, along with this study (Table [2](#cam4915-tbl-0002){ref-type="table-wrap"}). Of these 22 studies, 18 (82%) were case--control studies [8](#cam4915-bib-0008){ref-type="ref"}, [26](#cam4915-bib-0026){ref-type="ref"}, [27](#cam4915-bib-0027){ref-type="ref"}, [28](#cam4915-bib-0028){ref-type="ref"}, [29](#cam4915-bib-0029){ref-type="ref"}, [30](#cam4915-bib-0030){ref-type="ref"}, [31](#cam4915-bib-0031){ref-type="ref"}, [32](#cam4915-bib-0032){ref-type="ref"}, [33](#cam4915-bib-0033){ref-type="ref"}, [35](#cam4915-bib-0035){ref-type="ref"}, [41](#cam4915-bib-0041){ref-type="ref"}, [42](#cam4915-bib-0042){ref-type="ref"}, [43](#cam4915-bib-0043){ref-type="ref"}, [44](#cam4915-bib-0044){ref-type="ref"}, [45](#cam4915-bib-0045){ref-type="ref"}, [46](#cam4915-bib-0046){ref-type="ref"}, [47](#cam4915-bib-0047){ref-type="ref"}, [48](#cam4915-bib-0048){ref-type="ref"} and four (18%) were cohort studies [9](#cam4915-bib-0009){ref-type="ref"}, [10](#cam4915-bib-0010){ref-type="ref"}, [25](#cam4915-bib-0025){ref-type="ref"}, [49](#cam4915-bib-0049){ref-type="ref"}. Most studies were conducted in Asia (*N* = 13, 59%), followed by Central/Southern America (*N* = 5, 23%), Europe (*N* = 3, 14%), and the United States (*N* = 1, 5%). Eleven of these studies overlapped with other studies from the same study population. After conducting an initial overall meta‐analysis based on results from 16 studies with independent study populations including 1109 cases (Fig. [2](#cam4915-fig-0002){ref-type="fig"}), we found that the estimates were highly heterogenous (P~heterogeneity~\<0.001). The funnel plot appeared generally symmetrical, and there was no evidence of bias using either the Begg or Egger methods (*P* = 0.9 and 0.7, respectively). However, two studies lay outside the funnel: Caygill 1995 \[(standardized mortality ratio: 167 (54--391)\] and Serra 2002 \[OR: 0.5 (0.2--1.2)\]. After removing these two studies, the remaining 14 studies did not appear heterogeneous (*P* ~heterogeneity~ = 0.5) and produced a summary RR of 4.3 (3.2--5.8). We excluded the two outlying studies from further analyses.

###### 

Studies of *Salmonella* and gallbladder cancer (GBC)

  Reference                                                 Country           Study design                       Population   Specimen                     *S*. Typhi detection         Outcome                          Referent                                                                     *N* cases   *N* noncases   \% GBC *S*. Typhi+   \% noncase *S*. Typhi+   RR (95% CI)          Adjusted   Hand‐calculated
  --------------------------------------------------------- ----------------- ---------------------------------- ------------ ---------------------------- ---------------------------- -------------------------------- ---------------------------------------------------------------------------- ----------- -------------- -------------------- ------------------------ -------------------- ---------- -------------------------------------------
  Welton 1979 [8](#cam4915-bib-0008){ref-type="ref"}        USA               Case--control                      General      Stool                        Culture                      Hepatobiliary cancer mortality   Individuals from general population who died                                 37          1376           74.3%                32.2%                    6.6 (3.1--14.0)      No         Yes
  Mellemgaard 1988 [9](#cam4915-bib-0009){ref-type="ref"}   Denmark           Cohort                             General      Stool                        Culture                      Hepatobiliary cancer incidence   Denmark age, time, and sex‐specific incidence rates                          NS          NS                                                           3.9 (1.1--9.9)       Yes        No
  Caygill 1994 [10](#cam4915-bib-0010){ref-type="ref"}      UK                Cohort                             General      Stool                        Culture                      GBC mortality                    Morality rates                                                               83          NS             6.0%                                          167 (54.1--389)      Yes        No
                                                                                                                              Stool                        Culture                                                       Acute typhoid                                                                83          386            6.0%                                          52.3 (3.0--989.5)    No         Yes[a](#cam4915-note-0008){ref-type="fn"}
  Csendes 1994 [41](#cam4915-bib-0041){ref-type="ref"}      Chile             Case--control                      Hospital     Bile                         Culture                      Incident GBC                     Gallstone patients                                                           47          52             8.5%                 7.7%                     1.1 (0.3--4.7)       No         Yes
                                                                                                                              Bile                         Culture                                                       Acute cholecystitis                                                          47          19                                  26.3%                    0.3 (0.1--1.1)       No         Yes
                                                                                                                              Bile                         Culture                                                       Common bile duct stones                                                      47          39                                  10.3%                    0.8 (0.2--3.5)       No         Yes
  Caygill 1995 [25](#cam4915-bib-0025){ref-type="ref"}      UK                Cohort                             General      Stool                        Culture                      Hepatobiliary cancer mortality   Morality rates                                                               167         NS             3.0%                                          167 (54--391)        Yes        No
                                                                                                                              Stool                        Culture                      GBC mortality                    Acute typhoid                                                                167         507            3.0%                                          57.3 (3.1--1043.9)   No         Yes[a](#cam4915-note-0008){ref-type="fn"}
  Capoor 2008 [45](#cam4915-bib-0045){ref-type="ref"}       Bolivia, Mexico   Case--control                      Hospital     NA                           MD‐diagnosed typhoid         Prevalent GBC                    Abdominal surgery patients without biliary cancer or stones                  84          126                                                          12.7 (1.5--598)      Yes        No
                                                                                                                              Serum                        *S*. Typhi LPS                                                Abdominal surgery patients without biliary cancer or stones                  15          8              46.7%                50.0%                    0.9 (0.2--4.9)       No         Yes
                                                                                                                              Serum                        *S. Typhi LPS*                                                Gallstone/bile duct stone patients                                           15          10             46.7%                50.0%                    0.9 (0.2--4.3)       No         Yes
  Singh 1996 [30](#cam4915-bib-0030){ref-type="ref"}        India             Case--control                      Hospital     Bile                         Culture                      Prevalent GBC                    Gallstone patients                                                           38          67             13.2%                3.0%                     4.9 (0.9--26.8)      No         Yes
  Nath 1997 [27](#cam4915-bib-0027){ref-type="ref"}         India             Case--control                      Hospital     Bile                         Culture                      Prevalent GBC                    Patients with stones or no biliary pathology                                 28          73             14.3%                1.4%                     12 (1.3--112.7)      No         Yes
                                                                                                                              Bile                         Culture                                                       Stones only                                                                  28          56             14.3%                1.8%                     9.2 (0.97--86.4)     No         Yes
                                                                                                                              Bile                         Culture                                                       No biliary path only                                                         28          17             16.1%                2.9%                     6.7 (0.3--132.8)     No         Yes[a](#cam4915-note-0008){ref-type="fn"}
  Roa 1999 [62](#cam4915-bib-0062){ref-type="ref"}          Chile             Case--control                      Hospital     Bile                         Culture                      Prevalent GBC or dysplasia       Chronic and acute cholecystitis                                              29          579            1.7%                 0.8%                     2.1 (0.1--39.4)      No         Yes[a](#cam4915-note-0008){ref-type="fn"}
  Dutta 2000 [43](#cam4915-bib-0043){ref-type="ref"}        India             Case--control                      Hospital     Serum                        VI (ELISA)                   Incident GBC                     Gallstone patients                                                           37          80             16.2%                2.5%                     14 (1.8--92)         Yes        No
  Shukla 2000 [29](#cam4915-bib-0029){ref-type="ref"}       India             Case--control                      Hospital     Serum                        VI (IHA)                     Prevalent GBC                    Gallstone patients                                                           51          56             29.4%                10.7%                    3.9 (1.3--11.7)      Yes        No
                                                                                                                              Serum                        VI (IHA)                                                      No hepatobiliary disease                                                     51          40             29.4%                5.0%                     7.2 (2.2--23.4)      Yes        No
                                                                                                                              Serum                        Widal test                                                    Gallstone patients                                                           51          56             39.2%                42.9%                    0.9 (0.4--1.9)       No         Yes
                                                                                                                              Serum                        Widal test                                                    No hepatobiliary disease                                                     51          40             39.2%                40.0%                    0.97 (0.4--2.3)      No         Yes
  Serra 2002 [42](#cam4915-bib-0042){ref-type="ref"}        Chile             Case--control                      Hospital     NA                           Self‐report                  Prevalent GBC                    Gallstone patients                                                           114         114            9.6%                 7.9%                     0.5 (0.2--1.2)       Yes        No
  Pandey 2003 [28](#cam4915-bib-0028){ref-type="ref"}       India             Case--control                      Hospital     NA                           Self‐report                  Incident GBC                     Gallstone patients                                                           64          101            21.9%                12.9%                    1.3 (0.9--2.0)       No         Yes
  Hazrah 2004 [26](#cam4915-bib-0026){ref-type="ref"}       India             Case--control                      Hospital     Gallstones                   Culture                      Incident GBC                     83 chronic cholecystitis, 2 empyema, 1 periampullary cancer                  14          86             3.6%                 2.9%                     1.2 (0.1--25.5)      No         Yes[a](#cam4915-note-0008){ref-type="fn"}
  Yagyu 2004 [49](#cam4915-bib-0049){ref-type="ref"}        Japan             Cohort                             General      NA                           Self‐report                  GBC mortality                    Noncases                                                                     89          91895          2.2%                 1.4%                     1.6 (0.4--6.5)       No         Yes
                                                                                                                 Males only   NA                           Self‐report                                                   Male noncases                                                                34          38603          5.9%                 1.6%                     2.1 (0.5--8.7)       Yes        No
  Vaishnavi 2005 [33](#cam4915-bib-0033){ref-type="ref"}    India             Case‐control                       Hospital     Serum                        VI (ELISA)                   Prevalent GBC                    Gallbladder/bile duct stones                                                 27          196            7.4%                 10.2%                    0.7 (0.2--2.8)       No         Yes
                                                                                                                              Serum                        VI (ELISA)                                                    Cholangiocarcinoma, obstructive jaundice, or carcinoma of pancreas/ampulla   27          33             7.4%                 12.1%                    0.6 (0.2--1.6)       No         Yes
                                                                                                                              Serum                        VI (ELISA)                                                    Miscellaneous gastrointestinal ailments                                      27          112            7.4%                 9.8%                     0.7 (0.2--2.7)       No         Yes
                                                                                                                              Serum                        VI (ELISA)                                                    Miscellaneous diseases                                                       27          78             7.4%                 9.0%                     0.8 (0.2--2.7)       No         Yes
                                                                                                                              Serum                        VI (ELISA)                                                    Consecutive healthy blood donors                                             27          705            7.4%                 1.8%                     4.3 (1.1--16.1)      No         Yes
  Sharma 2007 [32](#cam4915-bib-0032){ref-type="ref"}       India             Case--control                      Hospital     Serum                        TO                           Prevalent GBC                    Gallstone patients                                                           65          125            40.0%                62.4%                    0.4 (0.2--0.7)       No         Yes
                                                                                                                              Serum                        TH                                                            Gallstone patients                                                           65          125            30.8%                9.6%                     4.2 (1.9--9.3)       No         Yes
                                                                                                                              Serum                        TO                                                            Laparotomy for diseases other than hepatobiliary tract                       65          200            40.0%                9.0%                     6.7 (3.4--13.5)      No         Yes
                                                                                                                              Serum                        TH                                                            Laparotomy for diseases other than hepatobiliary tract                       65          200            30.8%                11.0%                    3.6 (1.8--7.2)       No         Yes
                                                                                                                              Serum                        VI (IHA)                                                      Gallstone patients                                                           65          125            30.8%                9.6%                     4.2 (1.9--9.3)       No         Yes
                                                                                                                              Serum                        VI (IHA)                                                      Laparotomy for diseases other than hepatobiliary tract                       65          200            30.8%                11.0%                    3.6 (1.8--7.2)       No         Yes
                                                                                                                              Bile                         Culture                                                       Gallstone patients                                                           65          125            24.6%                3.2%                     9.9 (3.1--31.0)      No         Yes
  Capoor 2008 [46](#cam4915-bib-0046){ref-type="ref"}       India             Case--control                      Hospital     Tissue, gallstones, bile     Culture                      Prevalent GBC                    Cholelithiasis + acute cholecystitis                                         6           53             16.7%                3.8%                     5.1 (0.4--66.7)      No         Yes
  Nath 2008 [31](#cam4915-bib-0031){ref-type="ref"}         India             Case--control                      Hospital     Serum                        VI (IHA)                     Prevalent GBC                    Other gallbladder diseases                                                   52          223            38.5%                13.9%                    3.9 (2.0--7.6)       No         Yes
                                                                                                                              Serum                        VI (IHA)                                                      Healthy adults                                                               52          508            38.5%                9.3%                     6.1 (3.3--11.6)      No         Yes
                                                                                                                              Serum                        TO (Widal test)                                               Other gallbladder diseases                                                   52          223            23.1%                11.7%                    2.3 (1.1--4.9)       No         Yes
                                                                                                                              Serum                        TO (Widal test)                                               Healthy adults                                                               52          508            23.1%                13.4%                    1.9 (0.97--3.9)      No         Yes
                                                                                                                              Serum                        TH (Widal test)                                               Other gallbladder diseases                                                   52          223            21.2%                3.6%                     7.2 (2.7--19.0)      No         Yes
                                                                                                                              Serum                        TH (Widal test)                                               Healthy adults                                                               52          508            21.2%                11.8%                    2.0 (0.98--4.1)      No         Yes
                                                                                                                              Bile                         Culture                                                       Other gallbladder diseases                                                   52          223            3.8%                 0.9%                     4.5 (0.6--32.4)      No         Yes
                                                                                                                              Bile                         Culture                                                       Cadavers without gallbladder pathology                                       52          424            3.8%                 0.1%                     42.0 (2.0--887.8)    No         Yes[a](#cam4915-note-0008){ref-type="fn"}
                                                                                                                              Bile, stone, tissue, blood   PCR + flagellin sequencing                                    Other gallbladder diseases                                                   52          223            67.3%                42.6%                    2.8 (1.5--5.2)       No         Yes
                                                                                                                              Bile, stone, tissue, blood   PCR + flagellin sequencing                                    Cadavers without gallbladder pathology                                       52          424            67.3%                8.3%                     11.1 (6.5--22.0)     No         Yes
  Tewari 2010 [35](#cam4915-bib-0035){ref-type="ref"}       India             Case--control                      Hospital     Serum                        TO and TH (Widal)            Prevalent GBC                    Gallstone patients                                                           54          54             44.4%                24.1%                    2.5 (1.1--5.7)       No         Yes
                                                                                                                              Serum                        VI (IHA)                                                      Gallstone patients                                                           54          54             22.2%                9.3%                     2.8 (0.9--8.6)       No         Yes
                                                                                                                              Tissue                       Culture                                                       Gallstone patients                                                           54          54             6.5%                 0.9%                     7.7 (0.4--153.0)     No         Yes[a](#cam4915-note-0008){ref-type="fn"}
                                                                                                                              Bile                         PCR (*flagellin*)                                             Gallstone patients                                                           54          54             4.6%                 0.9%                     5.2 (0.2--110.7)     No         Yes[a](#cam4915-note-0008){ref-type="fn"}
                                                                                                                              Tissue                       PCR (*flagellin*)                                             Gallstone patients                                                           54          54             34.3%                0.9%                     55.2 (3.2--945.8)    No         Yes[a](#cam4915-note-0008){ref-type="fn"}
  Safaeian 2011 [47](#cam4915-bib-0047){ref-type="ref"}     China             Case--control (population‐based)   General      Serum                        VI (ELISA)                   Incident GBC                     Gallstone patients                                                           262         728            0.2%                 0.3%                     0.6 (0.03--11.6)     No         Yes[a](#cam4915-note-0008){ref-type="fn"}
  Koshiol 2016                                              Chile             Case--control (population‐based)   General      Serum                        VI (ELISA)                   Incident GBC                     Gallstone patients                                                           39          40             15.4%                5.0%                     3.1 (0.6--17.7)      Yes        No
                                                                                                                              Serum                        VI (ELISA)                                                    Population‐based controls                                                    39          39             15.4%                2.6%                     5.6 (0.6--52.8)      Yes        No
                                                                                                                              Serum                        VI (ELISA)                                                    Gallstone patients + population‐based controls                               39          79             15.4%                3.8%                     4.0 (0.9--18.3)      Yes        No

LCL, lower confidence limit; NA, not applicable; NS, not‐specified; TH, antibodies to flagellar Salmonella antigen; TO, antibodies to somatic Salmonella antigen; UCL, upper confidence limit; VI, antibodies to Vi *Salmonella* antibody.

Added 0.5 to 0 cells.
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![Relative risks (RRs) and 95% confidence intervals (CIs) for associations between *Salmonella* and gallbladder cancer (GBC) in the published literature.](CAM4-5-3310-g002){#cam4915-fig-0002}

Studies of Vi antibody seropositivity and bile culture produced similar results \[summary RR (95% CI): 4.6 (3.1--6.8) and 4.7 (1.5--14.6)\] (Table [3](#cam4915-tbl-0003){ref-type="table-wrap"}). Stool culture produced slightly higher \[summary RR 5.5 (3.0--10.4)\] but not substantially different \[ratio of RRs: 1.2 (0.6--2.5)\] estimates than Vi antibody‐based estimates. Combining bile culture and stool culture‐based estimates, the summary RR was 5.0 (2.7--9.3, *P* ~heterogeneity~ = 0.2). Estimates based on self‐report were much lower than Vi antibody‐based estimates \[(ratio of RRs: 0.3 (0.2--0.5)\]. Results did not vary greatly by additional study characteristics or exhibit notable heterogeneity with the possible exception of outcome referent group (Table [3](#cam4915-tbl-0003){ref-type="table-wrap"}). Estimates comparing GBC to controls from the general population \[summary RR (95% CI): 5.1 (3.4--7.6)\] or nonhepatobiliary patients and cadavers \[5.5 (2.2--13.9)\] tended to be stronger than those comparing to gallstones \[2.5 (1.4--4.2)\], although estimates using nonhepatobiliary patients or cadavers as referent were also more heterogeneous (*P* ~heterogeneity~=0.003 vs. 0.2).

###### 

Effect of study characteristics on the association between *Salmonella* and gallbladder cancer (GBC) in a meta‐analysis of the published literature

                                                                          Summary effect estimate[a](#cam4915-note-0009){ref-type="fn"}   Ratio of effect estimates         
  ---------------------------------------------------------- ---- ------- --------------------------------------------------------------- --------------------------- ----- ----------
  *Salmonella* detection method                                                                                                                                             
  VI antibody seropositivity                                 7    0.6     4.6                                                             3.1--6.8                    1.0    
  Bile culture                                               5    0.1     4.7                                                             1.5--14.6                   1.0   0.5--2.4
  Stool culture                                              2    0.4     5.5                                                             3.0--10.4                   1.2   0.6--2.5
  Self‐report                                                2    0.8     1.3                                                             0.9--2.0                    0.3   0.2--0.5
  Referent group                                                                                                                                                            
  Stones (gallstones and/or bile duct)                       10   0.2     2.5                                                             1.4--4.2                    1.0    
  General population[b](#cam4915-note-0010){ref-type="fn"}   6    0.6     5.1                                                             3.4--7.6                    1.9   0.7--4.8
  Hepatobiliary patients                                     4    0.005   2.1                                                             0.4--11.0                   0.9   0.3--2.9
  Nonhepatobiliary patients and cadavers                     6    0.003   5.5                                                             2.2--13.9                   2.2   0.8--5.9
  Study design                                                                                                                                                              
  Case--control                                              12   0.6     4.6                                                             3.3--6.4                    1.0    
  Cohort                                                     2    0.3     2.7                                                             1.1--6.6                    0.6   0.2--1.5
  Region                                                                                                                                                                    
  Asia                                                       8    0.5     4.3                                                             3.0--6.3                    1.0    
  Central/South America                                      4    0.4     2.5                                                             1.0--6.3                    0.6   0.2--1.6
  Population                                                                                                                                                                
  Hospital                                                   9    0.5     4.4                                                             3.0--6.4                    1.0    
  General                                                    5    0.3     3.9                                                             2.1--7.2                    1.0   0.5--1.8
  Statistical analysis                                                                                                                                                      
  Crude/hand‐calculated                                      8    0.3     4.3                                                             2.9--6.5                    1.0    
  Adjusted                                                   6    0.6     3.9                                                             2.2--7.0                    0.9   0.4--1.7

Random effects relative risks (RRs), 95% confidence limits (95% CIs).

Normal patients, population‐based controls, mortality rates, incidence rates.

John Wiley & Sons, Ltd

Discussion {#cam4915-sec-0014}
==========

In Chile, which has among the highest GBC incidence and mortality rates worldwide, we observed a trend toward a higher prevalence of elevated Vi antibody titers among GBC cases compared to gallstone and population‐based controls. Although the ORs were borderline significant, the magnitudes were high, with a fourfold increase for GBC cases compared to combined gallstone and population‐based controls and a 3.1‐fold and 5.6‐fold increase, respectively, for GBC cases compared separately to gallstone controls and population‐based controls.

These magnitudes are comparable to those from other studies. Our adjusted OR of 4.0 (0.9--18.3) for high‐titer Vi antibody seropositivity and GBC was similar to the meta‐analysis summary RR for Vi antibody seropositivity \[(summary RR: 4.6 (3.1--6.8)\]. In the meta‐analysis, associations between *S. *Typhi and GBC remained even when stratified by factors like *S. *Typhi detection method, outcome referent group, study design, geographical region, source of study population, and statistical adjustment. This consistency is striking.

However, the magnitude of the estimates appeared to be affected by the *S. *Typhi exposure assessment and outcome referent group used. Estimates based on self‐report produced a summary RR of 1.3 (0.9--2.0), likely reflecting poor measurement of exposure to *S. *Typhi since most people do not know that they have been exposed. With regard to outcome referent group, in our study, we combined gallstone and population‐based controls to gain precision since both referent groups produced strong ORs separately. The magnitude of the OR was stronger for GBC compared to population‐based controls than compared to gallstone controls, however. Similarly, in the meta‐analysis, general population controls and nonhepatobiliary patients/cadavers tended to produce stronger RRs than estimates compared to gallstone controls. *S. *Typhi is associated with gallstones. It is believed that this association is due to *S. *Typhi\'s propensity to form biofilms on gallstones [50](#cam4915-bib-0050){ref-type="ref"} and to colonize abnormal gallbladder mucosa. However, potential reverse causality cannot be ruled out. Additional research is needed to tease apart the exact role of *S. *Typhi across the natural history of GBC carcinogenesis.

This need is highlighted by the fact that on an individual study level, the association with GBC is not always consistent for *S. *Typhi detected in samples from the gallbladder or gastrointestinal tract. For example, a previous study conducted in Santiago, Chile, when typhoid fever incidence was still high, found a similar prevalence of *S. *Typhi in bile cultures from GBC cases (8.5%) and gallstones controls (7.7%) and thus no association between *S. *Typhi and GBC \[OR: 1.12 (0.26--4.74)\] [51](#cam4915-bib-0051){ref-type="ref"}. A systematic study of bile specimens from cholecystectomies performed in Chile in the early 1980′s found *S. *Typhi or *S. *Paratyphi in 7.3% (73/1000) of bile cultures [52](#cam4915-bib-0052){ref-type="ref"}, but this prevalence may have included some transient *S. *Typhi or *S. *Paratyphi infections (i.e., infections that are detected in the first 12 months after recovery from acute typhoid fever or after subclinical infection), as well as chronic infections. A similar situation may be occurring in India today, where typhoid fever incidence rates in some areas are currently higher than those of Chile in the 1980′s and *S. *Typhi isolation in bile samples from GBC patients ranges from 14.3% [27](#cam4915-bib-0027){ref-type="ref"} to 25% [32](#cam4915-bib-0032){ref-type="ref"}. Chile, in contrast, no longer has a high *S. *Typhi incidence rate. In our study, we did not succeed in culturing *S. *Typhi or in identifying *S. *Typhi DNA in bile, gallstones, gallbladder tissue, or stool samples, which could reflect reduced exposure more than 20 years after the control of typhoid hyperendemicity, or it may be due to lack of power given the small number of bile, gallstone, and tissue samples. Alternatively, the typhoid bacilli may reside in bile ducts rather than in the gall bladder *per se* in some chronic carriers. In any case, these findings highlight the value of the Vi antibody assay in population studies.

We did not have the ability to evaluate serotypes other than S. Typhi in the current study. *Salmonella* Paratyphi A and B do not produce Vi polysaccharide. *S*. Paratyphi C, expresses Vi, but it is a very rare cause of enteric fever [53](#cam4915-bib-0053){ref-type="ref"} thus, the Vi antibody assay essentially only detects *S*. Typhi. Nevertheless, it is important to note that chronic *S*. Paratyphi A and *S*. Paratyphi B carriage also appear to contribute to gallbladder carcinogenesis. A previous study in Chile isolated *S. *Paratyphi A in 1.5% of 1000 bile samples and *S. *Paratyphi B in 8.8%, accounting for 6.8% and 41.1% of all *Salmonella* species isolated [52](#cam4915-bib-0052){ref-type="ref"}. In addition, Caygill et al. reported that their cohort of chronic *Salmonella* carriers included 61 *S. *Paratyphi A, B, or C carriers, 21 *S. *Typhi carriers, and one carrier with both *S*. Paratyphi and *S. *Typhi, although they did not describe the serotypes of the five GBC cases that developed among these carriers [10](#cam4915-bib-0010){ref-type="ref"}. Singh et al. reported one *S*. Paratyphi carrier and four *S*. Typhi carriers out of 38 GBC cases (2.6% and 10.5%, respectively) [30](#cam4915-bib-0030){ref-type="ref"}. Finally Nath et al. reported that 3.5% of 28 GBC cases had *S*. Paratyphi A and 10.7% had *S*. Typhi, while the corresponding figures were 0% and 1.8% among the 56 gallstone controls [27](#cam4915-bib-0027){ref-type="ref"}. These findings are intriguing, although information about serotypes other than *S*. Typhi are quite limited and require larger studies targeted toward these serotypes to draw conclusions.

In addition to the epidemiological evidence, several lines of biological evidence suggest that *S. *Typhi may contribute to gallbladder carcinogenesis. The capsular polysaccharide expressed by *S*. Typhi has been shown to suppress the inflammatory response of intestinal mucosa [54](#cam4915-bib-0054){ref-type="ref"}, [55](#cam4915-bib-0055){ref-type="ref"}, [56](#cam4915-bib-0056){ref-type="ref"}, while non‐typhoidal *Salmonella* serovariants such as *S*. Typhimurium and *S*. Enteritidis cause strong inflammatory responses in intestinal mucosa, including an influx of polymorphonuclear neutrophils. ViaB genetic mutants of *S*. Typhi that do not express Vi polysaccharide cause significantly more mucosal inflammation in a bovine intestinal loop model than wild‐type *S. *Typhi [55](#cam4915-bib-0055){ref-type="ref"}. If *S. *Typhi suppresses immune response in the gallbladder mucosa as well, it may create a chronic, low‐level inflammatory or regulatory immune environment that enhances the propensity to develop carcinogenic changes of the mucosa. *Salmonella*, especially *S. *Typhi [57](#cam4915-bib-0057){ref-type="ref"}, is well known to form biofilms upon contact with cholesterol gallstones and similar substrates, and the genes it expresses vary depending on whether it is in a biofilm state [50](#cam4915-bib-0050){ref-type="ref"}, [58](#cam4915-bib-0058){ref-type="ref"}. *S. *Typhi produces a number of carcinogens, including bacterial glucoronidase, secondary bile acids, nitroso compounds, and cytolethal distending toxin (CDT), a genotoxin with immunomodulatory capability that causes DNA damage in the nucleus of the infected cell [59](#cam4915-bib-0059){ref-type="ref"}. DNA damage may also result from increased free radical concentration due to chronic *S. *Typhi infection [60](#cam4915-bib-0060){ref-type="ref"}. Furthermore, a recent study found that *S. *Typhi could induce transformation in murine gallbladder organoids and fibroblasts, although only in the presence of predisposing mutations (i.e., inactivated *TP53* mutations and *c‐MYC* amplification), and that by causing such mutations in gallbladder tissue, *S. *Typhi may have stable transformative effects that remain even after the infection is eradicated [61](#cam4915-bib-0061){ref-type="ref"}. However, such mechanistic studies might best be done with *Salmonella* grown in biofilms that mimic the way they exist in the colonized gallbladder.

This study has weaknesses, of which sample size and lack of bile, tissue, and stool specimens in a proportion of participants are the most obvious. A future, larger study in Chile would address this issue. In addition, as a case--control study, we cannot rule out the potential for reverse causality (i.e., that *S. *Typhi detection may be due to the presence of cancer rather than the cause of the cancer), although the consistency of the positive associations between *S. *Typhi and GBC in the meta‐analysis, particularly among the cohort studies, argues against reverse causality. The meta‐analysis was limited by the heterogeneity of the study methods, such as the *S. *Typhi diagnostic methods used.

This study also has a number of strengths. It was conducted in a country with high rates of GBC and a past high incidence of *S. *Typhi in multiple regions. The controls were representative of the population from which the cases arose, reducing the potential for bias between comparison groups, and the extensive epidemiologic data collected allowed for evaluation and control of confounders. In addition, we conducted a large meta‐analysis of over 1000 GBC cases, which allowed us to examine variability by study characteristics. Despite the heterogeneity in study methods, the associations between *S*. Typhi and GBC were consistently positive.

In this study, we found evidence supporting an association between high Vi antibody titer levels and GBC that was consistent with summary estimates from our meta‐analysis of the published literature. While the specific mechanisms involved in *S. *Typhi‐related carcinogenesis may not be clear, the positive association between *S. *Typhi and GBC in the published literature is surprisingly consistent, despite differences in study design. Studies are underway to identify the Vi antibody level cut point to screen for chronic biliary carriers using biotinylated Vi and antigen. In addition, transdisciplinary research between epidemiologists and basic scientists is needed to establish the nature of the association between *S. *Typhi and GBC. Future studies would ideally include both circulating markers of *S. *Typhi exposure and local measures in bile and stool to provide a more complete picture of infection status. Such studies may help inform public health policies regarding *S. *Typhi carriers.
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**Table S1**. Association between high titers of IgG antibody to the Vi capsular polysaccharide of *Salmonella enterica* serovar Typhi in gallbladder cancer cases compared to gallstone controls and population‐based controls without gallstones (combined) using various cut‐offs for the definition of high titers.

**Table S2**. Summary of bacteria detected in bile, gallstones, gallbladder tissue, and stool from gallbladder cancer (GBC), gallstone, and population‐based participants in the Shanghai Biliary Tract Cancer Study.
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Click here for additional data file.
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